# EDGAR Filing Document

**Accession Number:** 0001412558
**File Stem:** 0001104659-26-000053
**Filing Date:** 2026-1
**Character Count:** 7956
**Document Hash:** b2d6a3b51508099d2f57f33408c5b11a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-000053.hdr.sgml**: 20260102

**ACCESSION NUMBER**: 0001104659-26-000053

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260101

**FILED AS OF DATE**: 20260102

**DATE AS OF CHANGE**: 20260102

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evotec SE
- **CENTRAL INDEX KEY:** 0001412558
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34041
- **FILM NUMBER:** 26500156

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 22419
- **BUSINESS PHONE:** 49-40-560-810

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 22419

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Evotec AG
- **DATE OF NAME CHANGE:** 20070917

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January, 2026**

**COMMISSION FILE NUMBER 001-34041**

**Evotec SE**<br> (Translation of registrant's name into English)

**Essener Bogen 7**

**22419 Hamburg**

**Germany**

**Tel: +49 40 560810**<br> (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On January 1, 2026, Evotec SE (the "Company") issued a press release announcing the appointment of Dr. Sarah Fakih as Head of Global Communications and Investor Relations attached hereto as Exhibit 99.1.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description of Exhibit</u>** |
| [99.1](tm261640d1_ex99-1.htm) | [Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations](tm261640d1_ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Evotec SE** | **Evotec SE** |
| By: | /s/ Christian Wojczewski |
|  | Name: Christian Wojczewski |
|  | Title: Chief Executive Officer |

---

Date: January 1, 2026

## Exhibit 99.1

**Exhibit 99.1**

![](tm261640d1_ex99-1img001.jpg)

**Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations**

&nbsp;&nbsp;&nbsp;&nbsp;· *Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment* 

 

------

 

 

**Hamburg, Germany, January 1, 2026:**

Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. In this strategic role, Dr. Fakih will lead Evotec's newly integrated Global Communications and Investor Relations function.

Reporting directly to CEO Dr. Christian Wojczewski, she will bring together both teams to strengthen alignment, clarity and engagement across stakeholders. The integration of Communications and Investor Relations supports Evotec's focus on a clear and consistent articulation of its strategy, scientific leadership and value creation. The appointment follows the departure of Volker Braun, who successfully led Evotec's Investor Relations and ESG function over the past five years.

**Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:** "Clear and credible communication is essential as we continue to execute our strategy. Sarah's extensive experience across science, investor relations and corporate communications makes her ideally suited to this role. I would like to thank Volker for his dedicated contributions to our investor relations and ESG during the past five years and wish him all the best for the future."

Dr. Fakih brings more than 15 years of experience in life sciences, with a strong leadership track record in capital markets strategy and corporate messaging. She has held senior roles at U.S. listed companies, including QIAGEN, MorphoSys, and most recently at CureVac. She holds a PhD in Chemistry.

**About Evotec SE**

*Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.*

*Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.*

*With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.*

Page 1 of 2

![](tm261640d1_ex99-1img002.jpg)

*Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.*

 

*With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.*

*Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at <u>www.evotec.com</u> and follow us on <u>LinkedIn</u> and X/Twitter <u>@Evotec</u>.*

 

**Forward-looking statements**

*This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.*

 

**For further information, please contact: Investor Relations and Media Contact**

*Dr. Sarah Fakih*

*EVP Head of Global Communications & Investor Relations*

*<u>Sarah.Fakih@evotec.com</u>*

Page 2 of 2